ArticleEuropean clinical respiratory journal2025
Exploring the potential of cell-free tumor DNA in bronchoscopic diagnosis of peripheral lung lesions-the DRILL study.
Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liquid biopsy biomarkers for accurate detection of malignant pulmonary nodules: a meta-analytic approach.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small lung lesions can represent early-stage lung cancer but are difficult to diagnose. The bronchoscopic approach has the lowest risk of complications; however, the diagnostic yield is generally lower compared to trans-thoracic biopsies. Cell-free tumor DNA (cftDNA) is fragmented DNA stemming from a tumor. CftDNA in the form of methylated HOXA9 has previously been detected in bronchial lavage (BL) and has been proposed as an adjunct to conventional biopsies to improve diagnostic yield. The aim of this study was to assess whether methylated HOXA in BL could be utilized as an add-on diagnostic modality for bronchoscopic tissue sampling. Method: The study was conducted as a prospective diagnostic accuracy study in accordance with STARD guidelines. Patients undergoing bronchoscopy for diagnosing peripheral lung lesions were included. During bronchoscopy, BL samples were collected before and after biopsy. The samples were analyzed for methylated HOXA using a predefined cutoff and compared to histopathology or the result of CT surveillance. Results: One hundred seventy-two patients were included, with samples collected from 155 patients. A definite diagnosis was obtained from bronchoscopic biopsies in 47.1%. The sensitivity and specificity of methylated HOXA9 in BL were 68.0 (58.0-76.8) and 76.3 (59.8-88.6), respectively. The positive likelihood ratio of methylated HOXA9 in patients with a non-diagnostic biopsy was 2.11. Conclusion: The diagnostic accuracy of methylated HOXA9 in BL was too low to confirm or refute malignancy following an inconclusive biopsy; however, BL was superior to blood samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.